Kylin Therapeutics, a biotechnology company, employs an RNA nanoparticle technology platform called “pRNA†to exploit the enormous potential of RNA interference (RNAi) for treatment of many common diseases. The platform has enormous potential to meet the huge market opportunity for treating cancer and other diseases with RNA-based therapeutics. The unique capabilities of the platform have enabled Kylin to overcome many challenges in the development of RNA-based therapies.